Previous 10 | Next 10 |
CohBar (NASDAQ: CWBR ): Q4 GAAP EPS of -$0.10. More news on: CohBar, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
MENLO PARK, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases, today reported its financial results for the fourth quarter ended December 31, 2018. ...
MENLO PARK, Calif., March 04, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases, announced today that the company will release its fourth quarter 2018 financial re...
MENLO PARK, Calif., Feb. 11, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases, today announced the appointment of Phyllis Gardner, M.D., to its Board of Directors and ...
Clinical Trials NASH is a progressive chronic liver disease with many causal pathogenic factors. We have learnt from research that dysregulation of the glucose and lipid metabolic pathways could be associated with the development of NASH. Inflammation and activation of the apoptotic (i.e. ce...
MDPs: A Cure-All, or Just Unwarranted Hype? CohBar ( CWBR ) was founded on the premise that dysfunctional mitochondria play a key role in regulating the driving forces behind age-related diseases. According to the thesis touted by the company, mitochondrially secreted peptides have cytoprote...
More news on: Datawatch Corporation, JinkoSolar Holding Co., Ltd., Yulong Eco-Materials, , Stocks on the move, Read more ...
Thinly traded micro cap CohBar ( CWBR -39% ) slumps on more than double normal volume, albeit on turnover of only 229K shares, in reaction to the suspension of a Phase 1 clinical trial evaluating NASH and obesity candidate CB4211. The company took action in order to address mild injectio...
CB4211 Phase 1 Clinical Trial Temporarily Suspended to Address Injection Site Reactions Will Host Conference Call on November 6, 2018 at 11:00 a.m. Eastern Time MENLO PARK, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company...
MENLO PARK, Calif., Oct. 31, 2018 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases, announced today that it will release its third quarter 2018 financial results after the ...
News, Short Squeeze, Breakout and More Instantly...
3D Systems Corporation (DDD) is expected to report $-0.11 for Q1 2024 ZW Data Action Technologies Inc. (CNET) is expected to report for Q1 2024 Celularity Inc. (CELU) is expected to report for Q1 2023 DMK Pharmaceuticals Corporation (DMKPQ) is expected to report for Q1 2024 Atlant...
ADDvantage Technologies Group Inc. (AEYGQ) is expected to report for Q1 2024 ContraFect Corporation (CFRXQ) is expected to report for Q1 2024 American Clean Resources Group Inc (ACRG) is expected to report for Q1 2024 Atlantic Lithium Ltd Ord Fully Paid (ALLIF) is expected to report f...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...